As of January 1, 2026, Medicare drug prices negotiated under the Inflation Reduction Act (IRA) are in effect for select high-spend Medicare Part D drugs. Unlike the proposed 340B rebate pilot, which remains paused, IRA pricing has moved forward as scheduled and is now being operationalized across the Medicare Part D program.
While the IRA does not amend the 340B statute, it introduces a new federally mandated pricing construct that is expected to have downstream effects on 340B operations. Covered Entities that dispense or administer drugs subject to Medicare price negotiation may begin to see changes in reimbursement dynamics and operational workflows, even though core 340B eligibility and purchasing rules remain unchanged.
Key Takeaways for 340B Covered Entities
- The IRA does not change 340B eligibility or ceiling prices. Covered Entities may continue purchasing eligible drugs at 340B pricing.
- Medicare reimbursement is changing. For select high-spend Part D drugs, Medicare’s negotiated Maximum Fair Prices (MFPs) are expected to lower effective Part D payment amounts.
- 340B savings may decrease for affected drugs. As Medicare reimbursement declines, the spread between 340B acquisition cost and Medicare payment may narrow.
- Impacts are limited to Medicare Part D. Non-Medicare claims and 340B compliance requirements remain unchanged.
- Operational complexity is increasing. Covered Entities and contract pharmacies may encounter new claim edits, reconciliation processes, and manufacturer or PBM information requests.
- Clear internal coordination is essential. Distinguishing IRA-driven reimbursement changes from 340B requirements can help avoid unnecessary disputes and workflow disruptions.
What the IRA Changes
Under the IRA, Medicare has established Maximum Fair Prices (MFPs) for a defined set of high-spend Medicare Part D drugs, as outlined by the CMS Medicare Drug Price Negotiation Program.
Key considerations include:
- Manufacturers must operationalize access to MFPs through Medicare Part D–specific mechanisms, which may include existing manufacturer–PBM platforms used for pricing reconciliation and claims adjustments.
- MFPs do not replace 340B ceiling prices.
- Covered Entities may continue purchasing eligible drugs at 340B pricing where applicable.
Although 340B acquisition costs remain unchanged, MFPs add another federally mandated pricing layer alongside existing 340B, Medicaid, and commercial pricing structures. This creates additional complexity in how purchasing, billing, and reimbursement workflows interact, particularly for Medicare Part D claims.
How IRA Pricing Affects 340B Savings
340B savings are generated from the difference between drug acquisition cost and payer reimbursement, including Medicare Part D.
With IRA pricing in effect:
- The negotiated MFP becomes the Medicare price benchmark for selected Part D drugs.
- Effective payment amounts associated with Medicare Part D claims are expected to decrease, depending on plan design and PBM contracting mechanics.
- As a result, the spread between the 340B purchase price and Medicare-related payment may narrow.
Illustrative example: If a drug is purchased at a 340B price of $600 and Medicare previously reimbursed $1,000, the savings generated on that claim would be $400. If IRA pricing reduces Medicare reimbursement to $800, the drug is still purchased at $600, but the savings generated on that claim would decrease to $200.
Contract Pharmacy and Operational Considerations
Covered Entities may experience IRA-related impacts through:
- Lower effective payment amounts on Medicare Part D claims for negotiated drugs
- Changes in contract pharmacy dispensing margins or fee arrangements tied to Medicare volume
- New or revised claim edits, explanations of benefits, or information requests from manufacturers or PBMs
These changes are driven by Medicare pricing policy and:
- Do not affect non-Medicare claims
- Do not alter 340B eligibility, purchasing requirements, or compliance obligations
Depending on transaction structure and eligibility, manufacturers may be required to ensure access to the lowest applicable federal price—either MFP or 340B—further increasing operational complexity without changing the underlying 340B compliance framework.
Looking Ahead
Several drugs selected for Medicare price negotiation were also included in HRSA’s proposed 340B rebate pilot. Although the pilot remains paused, the overlap underscores growing interaction between Medicare pricing policy and 340B operations for high-cost outpatient drugs.
IRA drug pricing is now fully implemented, and as additional drugs are selected in future years, Medicare pricing will play an increasingly significant role in shaping drug economics for Covered Entities. While 340B purchasing and eligibility rules remain unchanged, the convergence of multiple federal pricing programs adds complexity to reimbursement and margin analysis.
As Covered Entities navigate these changes, clarity into how Medicare pricing and 340B economics intersect is increasingly important. Our team at ACI helps Covered Entities monitor these impacts and ensure they can adapt with confidence.